Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Zilli T.
- Achard V.
- Dal Pra A.
- Schmidt-Hegemann N.
- Jereczek-Fossa B.A.
- Lancia A.
- Ingrosso G.
- Alongi F.
- Aluwini S.
- Arcangeli S.
- Blanchard P.
- Couñago F.
- Créhange G.
- Dirix P.
- Gomez Iturriaga A.
- Guckenberger M.
- Pasquier D.
- Sargos P.
- Scorsetti M.
- Supiot S.
- Tree A.C.
- Zapatero A.
- Le Guevelou J.
- Ost P.
- Belka C.
Grupos
Abstract
Background and purpose: Oligometastatic prostate cancer is a new and emerging treatment field with only few prospective randomized studies published so far. Despite the lack of strong level I evidence, metastasis-directed therapies (MDT) are widely used in clinical practice, mainly based on retrospective and small phase 2 studies and with a large difference across centers. Pending results of ongoing prospective randomized trials, there is a clear need for more consistent treatment indications and radiotherapy practices. Material and methods: A European Society for Radiotherapy and Oncology (ESTRO) Guidelines Committee consisting of radiation oncologists’ experts in prostate cancer was asked to answer a dedicated questionnaire, including 41 questions on the main controversial issues with regard to oligometastatic prostate cancer. Results: The panel achieved consensus on patient selection and routine use of prostate-specific membrane antigen positron emission tomography (PSMA PET) imaging as preferred staging and restaging imaging. MDT strategies are recommended in the de novo oligometastatic, oligorecurrent and oligoprogressive disease setting for nodal, bone and visceral metastases. Radiation therapy doses, volumes and techniques were discussed and commented. Conclusion: These recommendations have the purpose of providing standardization and consensus to optimize the radiotherapy treatment of oligometastatic prostate cancer until mature results of randomized trials are available. © 2022 The Author(s)
Datos de la publicación
- ISSN/ISSNe:
- 0167-8140, 1879-0887
- Tipo:
- Article
- Páginas:
- 199-207
- PubMed:
- 36228761
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 1,946 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
RADIOTHERAPY AND ONCOLOGY ELSEVIER IRELAND LTD
Documentos
- No hay documentos
Filiaciones
Keywords
- Consensus; Delphi Technique; Humans; Male; Prospective Studies; Prostatic Neoplasms; Retrospective Studies; prostate specific membrane antigen; adult; Article; bone metastasis; cancer patient; cancer radiotherapy; cancer staging; clinical article; consensus; controlled study; Delphi study; human; lymph node metastasis; male; medical expert; patient selection; phase 2 clinical trial; positron emission tomography; prostate cancer; questionnaire; radiation oncologist; radiation oncology; radiotherapy dosage; randomized controlled trial; systemic therapy; visceral metastasis; pathology; prospective study; prostate tumor; retrospective study
Cita
Zilli T,Achard V,Dal A,Schmidt N,Jereczek BA,Lancia A,Ingrosso G,Alongi F,Aluwini S,Arcangeli S,Blanchard P,CONDE A,Couñago F,Créhange G,Dirix P,Gomez A,Guckenberger M,Pasquier D,Sargos P,Scorsetti M,Supiot S,Tree AC,Zapatero A,Le J,Ost P,Belka C. Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus. Radiother. Oncol. 2022. 176. p. 199-207. IF:5,700. (1).
Portal de investigación